Diagnostic utility of serum prostate-specific antigen and circulating inflammatory markers for differentiating prostate cancer from benign prostatic hyperplasia.

ABSTRACT:

Objective

To assess the diagnostic performance of serum prostate-specific antigen (PSA), the Prostate Health Index (PHI), and peripheral blood inflammatory markers (neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), neutrophil-apolipoprotein A1 ratio (NAR) apolipoprotein A1 (ApoA1)) in differentiating prostate cancer (PCa) from biopsy-negative benign prostatic hyperplasia (BPH), and to construct an optimized machine learning diagnostic model.

Methods

A retrospective analysis was conducted on 701 patients referred for prostate biopsy between March 2018 and January 2024, including 421 PCa and 280 BPH cases. Patients were divided into training (60%; n=421), validation (20%; n=140), and test (20%; n=140) cohorts. LASSO regression identified key predictors, which

SUBMITTER: Luo D 

PROVIDER: S-EPMC12696541 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature